RxDoctor Payments Data

Jeffrey Koretzky, MD

Internal Medicine · Howell, NJNPI 1942271283

Payments from drug & device makers

$2,497in general payments, 2019–2025

Across 170 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$611
  • GSK$594
  • AbbVie$271
  • Amarin Pharma, Inc.$139
  • Boston Scientific$88
  • Abbott$86
  • plus $707 from 21 others

What the payments were for

  • Food & beverage$2,497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,497 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$327,047
Medicare patients
368
Services billed
4,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$81,236
JanuviaSitagliptin Phosphate49$58,871
EliquisApixaban63$57,648
FarxigaDapagliflozin Propanediol48$45,594
JanumetSitagliptin Phos/Metformin Hcl36$40,275
JardianceEmpagliflozin33$29,651
OzempicSemaglutide15$16,425
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$13,532
Breo ElliptaFluticasone/Vilanterol11$11,830
Amlodipine-ValsartanAmlodipine Besylate/Valsartan124$9,251
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid52$8,414
FenofibrateFenofibrate Nanocrystallized106$3,753
Albuterol Sulfate HfaAlbuterol Sulfate133$3,348
Levothyroxine Sodium274$3,206
Alprazolam331$3,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$52$99,14685 claims
GSKTrelegy Ellipta, Breo Ellipta$594$93,066112 claims
AstraZenecaFarxiga, Breztri Aerosphere$611$59,12666 claims
PfizerEliquis$85$57,64863 claims
Novo NordiskOzempic$48$16,42515 claims
AbbVieSynthroid$271$1,78333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Howell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →